【藥品性質提示】 ★必確認為低血磷、不可高血鉀。 #高警訊藥品

磷酸鹽補充 Treatment and prevention of hypophosphatemia in adult and pediatric patients ≥12 years of age

Electrolyte Supplement, Parenteral
Phosphorus is involved in many significant metabolic and enzymatic reactions in almost all organs and tissues. It exerts a modifying influence on the steady state of calcium levels, a buffering effect on acid-base equilibrium and a primary role in the renal excretion of hydrogen ion.
Potassium is the major cation of intracellular fluid and is essential for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion.

Distribution:
1. Enters cells via active transport from extracellular fluid; ~85% of serum phosphates is free and ultra-filterable
2. Protein binding: 15%
Excretion:
Primarily urine (>80% to 90% of dose reabsorbed by the kidney); skin and feces (small amounts).

Hyperphosphatemia, hyperkalemia, hypercalcemia, significant hypocalcemia

Use caution in pregnant women with other medical conditions (eg, preeclampsia; may be more likely to develop hyperkalemia).

Phosphorus, sodium, and potassium are normal constituents of human milk.

1. Cardiovascular: Bradycardia, cardiac arrhythmia, chest pain, ECG changes, edema, heart block, hypotension, localized phlebitis, prolonged QT interval on ECG
2. Endocrine & metabolic: Decreased serum magnesium, hyperkalemia, hyperphosphatemia, hypocalcemia
3. Gastrointestinal: Diarrhea, nausea, stomach pain, vomiting
4. Genitourinary: Decreased urine output
5. Nervous system: Confusion, lethargy, paralysis, paresthesia, seizures
6. Neuromuscular & skeletal: Asthenia, tetany
7. Renal: Acute renal failure
8. Respiratory: Dyspnea

Hypophosphatemia:
Phosphorous 8~64mM in divided dose
Prevention of urethral:
Phosphorous 32mM/day in divided dose
Hyperalimentation:
Each gram of glucose combining with phosphorous 0.04 to 0.048mM

1. Mild to mederate impairment: There are no specific dosage adjustments provided in the manufacturer's labeling.
2. Severe impairment: use only with extreme caution and close monitoring
3. CRRT: Decrease initial dose by at least 50%

There are no dosage adjustments provided in the manufacturer's labeling. Use with caution.

Physically compatible with D5W or NS at concentration of 160 mEq/L